Emergent BioSolutions earnings release, August 5, 2026

Emergent BioSolutions Inc. (EBS) · Form 8-K, Item 2.02 · Filed · SEC filing

EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

• Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year

• Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge

• Second Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior year

• Second Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior year

• Second Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an improvement of 1,800 bps versus prior year

• Restructuring business operations to align resourcing to current needs; expected to result in annualized savings of approximately $40 million when fully implemented

GAITHERSBURG, Md., August 5, 2026 —Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026.

“Emergent delivered a strong second quarter, significantly exceeding the high end of our guidance range with revenues of $234 million, primarily driven by accelerated MCM/biodefense contract modifications secured with the U.S. government. This performance reflects the focus, discipline and commitment of our teams, and it reinforces the strength of our mission, our portfolio and the steadiness of our multi-year plan toward transformation," said Joe Papa, CEO of Emergent. "However, alongside of these strong results, we are at a critical juncture in our turnaround and transformation, primarily stemming from our naloxone business. Today we are implementing an organizational restructuring plan and taking proactive steps to strengthen our financial foundation, align the company to the realities of the naloxone business and preserve our ability to invest in the areas that matter most for Emergent’s future. Additionally, we seek to collaborate with AI partners for bioterrorism preparedness.”

FINANCIAL HIGHLIGHTS

(1)

Q2 2026 vs. Q2 2025¹

Year to Date ("YTD") 2026 vs YTD 2025

RECENT BUSINESS UPDATES

• Secured contract modification from U.S. government and completed delivery of approximately $52.7 million of ACAM2000®

(Smallpox and Mpox (Vaccinia) Vaccine, Live)

• Executed $64.5 million for BAT®

(Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)) contract modification with U.S. government

• Secured two new strategic manufacturing partnerships with:

◦ SAB Biotherapeutics to advance its type 1 diabetes candidate, SAB-142

◦ Substipharm Biologics to support its Japanese Encephalitis vaccine in the United States;

• Refinanced term loan with new $150 million facility and amended asset-backed loan facility

• Announced partnership with British Columbia to supply NARCAN®

Nasal Spray for the launch of the expanded BC Take Home Naloxone Program

• Supported National Naloxone Awareness Day to increase awareness of life-saving naloxone

• Partnered with professional baseball player Davis Schneider to raise awareness of NARCAN®

Nasal Spray in Canada

• Announced launch of new NARCAN®

Nasal Spray Carrying Case and multipack configurations to expand opioid overdose preparedness following U.S. FDA approvals on supplemental new drug applications

• Received Saudi Food and Drug Authority Approval for ACAM2000®

(Smallpox and Mpox (Vaccinia) Vaccine, Live)

• Received approval from Singapore Health Sciences Authority for expanded indication of ACAM2000®

(Smallpox and Mpox (Vaccinia) Vaccine, Live) to include mpox

• Announced participation in several international preparedness conferences

RESTRUCTURING UPDATES

• Efforts aim to improve overall cost structure, drive efficiencies and align resourcing to the current needs of the organization; includes reduction of approximately 90 roles

• Creation of a new Growth organization that integrates the capabilities of R&D, Business Development, Strategy into one function led by Stephanie Duatschek, Senior Vice President, Chief Global Strategy & Franchise Development Officer, who will assume the role of Executive Vice President, Chief Growth Officer, with responsibility for the Company’s strategic growth²

SECOND

QUARTER 2026 FINANCIAL PERFORMANCE

(1)

Revenues

The Company uses the following categories in discussing revenues:

• Naloxone — comprises contributions from NARCAN®

Nasal Spray and KLOXXADO®

Nasal Spray

• Anthrax MCM — comprises contributions from CYFENDUS®, BioThrax®, ANTHRASIL®, and Raxibacumab

• Smallpox MCM — comprises contributions from ACAM2000®, CNJ-016®

(VIGIV) and TEMBEXA®

• Other Products — comprises contributions from BAT®

• All Other Revenues — comprises revenues from the Services operating segment and contracts and grants revenues

Product Sales, net

(3)

Naloxone

For Q2 2026, revenues from Naloxone products decreased $15.1 million, or 22%, as compared with Q2 2025. The decrease was primarily attributable to lower sales of OTC NARCAN®, mostly driven by an unfavorable price-volume mix in the U.S. public interest channels, partially mitigated by increases in Canadian sales of branded NARCAN® and KLOXXADO® sales.

Anthrax MCM

For Q2 2026, revenues from Anthrax MCM products increased $0.7 million, or 6%, as compared with Q2 2025. The increase was primarily attributable to a more favorable pricing mix driven by international sales of BioThrax®. This increase was partially offset by the absence of international sales of ANTHRASIL® in the current period, compared to international sales in the prior-year period. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and the Company’s delivery of orders that follow.

Smallpox MCM... (truncated)pared with Q2 2025. The increase was primarily attributable to higher USG sales of ACAM2000® due to timing, higher CNJ-016®

(VIGIV) sales with a more favorable price and volume mix of U.S. and international sales and higher TEMBEXA® international sales due to timing. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and the Company’s delivery of orders that follow.

Other Products

For Q2 2026, revenues from Other Product sales increased $47.9 million as compared with Q2 2025. The increase was primarily due to higher USG and international BAT® sales due to timing.³

All Other Revenues

Services

For Q2 2026, revenues from Services increased $2.0 million, or 45%, as compared with Q2 2025. The increase was primarily attributable to production activity at the Company’s Winnipeg facility.

Contracts and Grants

For Q2 2026, revenues from contracts and grants decreased $3.1 million, or 29%, as compared with Q2 2025. The decrease was primarily due to lower Ebanga® related development work, reflecting timing and nature of work performed.

Operating Expenses

Cost of Product and Services Sales, Net

For Q2 2026, cost of product and services sales, net increased $30.2 million, or 45%, as compared with Q2 2025. The increase was driven by higher cost of MCM Product sales of $27.0 million and cost of Services of $3.3 million, partially offset by a decrease in cost of Commercial Product sales of $0.1 million.

Research and Development Expenses

For Q2 2026, R&D expenses decreased $3.3 million, or 26%, as compared with Q2 2025. The decrease was primarily due to lower project spend on Ebanga® related development work.

Selling, General and Administrative Expenses

For Q2 2026, SG&A expenses increased $0.9 million, or 2%, as compared with Q2 2025. The increase was primarily due to lower insurance reimbursement benefits recognized in the current year period compared with the prior year period, partially offset by lower compensation, marketing and administrative support expenses.

Impairment of Long-Lived Assets

For Q2 2026, impairment of long-lived assets was $191.3 million. This was the result of a non-cash impairment charge in the second quarter of 2026 related to our NARCAN® asset group within the Commercial reporting unit.

ADDITIONAL FINANCIAL INFORMATION

(1)

Capital Expenditures

For Q2 2026, capital expenditures decreased largely due to reduced development activities across the Company’s facilities.⁴

REPORTABLE SEGMENT INFORMATION

The Company manages the business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN®

Nasal Spray and KLOXXADO®

Nasal Spray; (2) a MCM Products segment consisting of Anthrax - MCM, Smallpox - MCM and Other products and (3) a services segment consisting of our Bioservices offerings (“Services”). Commercial Products and MCM Products are our two reportable segments. The Services operating segment no longer meets the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification 280, Segment Reporting, and as such is categorized within “All other revenues” along with “Contracts and Grants”. The Company evaluates the performance of these reportable segments based on revenues and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales but does not include inter-segment services. The Company does not allocate contracts and grants revenue, R&D, SG&A, amortization of intangible assets, interest and other income (expense) or taxes to its evaluation of the performance of these segments.

SECOND

QUARTER 2026 REPORTABLE SEGMENT RESULTS

Cost of Commercial Products sales decreased $0.1 million to $36.3 million for the quarter ended June 30, 2026. Despite decreases in U.S. sales volumes of OTC NARCAN® compared with the prior year period, cost of sales remained substantially flat due to increased costs and volumes associated with KLOXXADO® sales and Canadian sales of branded NARCAN®.

Commercial Products gross margin decreased $15.0 million, or 69%, to $6.7 million for the quarter ended June 30, 2026. Commercial Products gross margin percentage decreased 19 percentage points to 13% for the quarter ended June 30, 2026. The decrease was largely due to an unfavorable price and volume mix of OTC NARCAN® across most U.S. sales channels, partially offset by lower product costs related to Canadian sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $9.4 million and the portion of stock-based compensation expense recorded as cost of sales of $0.1 million.⁵

Cost of MCM product sales increased $27.0 million, or 105%, to $52.8 million for the quarter ended June 30, 2026. The increase was primarily attributable to higher product sales volumes for BAT®, ACAM2000®, CNJ-016®

(VIGIV), BioThrax®, and TEMBEXA®, as well as a significant non-recurring manufacturing cost related to the production of CYFENDUS®. These increases were partially offset by a decrease in cost of sales for ANTHRASIL® driven by lower sales volumes.

MCM Products gross margin increased $81.6 million to $107.4 million for the quarter ended June 30, 2026. MCM Product gross margin percentage increased 20 percentage points to 64% for the quarter ended June 30, 2026. The increase in gross margin percentage was primarily driven by a more favorable sales mix and increased sales volumes, which improved absorption of fixed manufacturing costs. These improvements were partially offset by a significant non-recurring manufacturing cost related to the production of CYFENDUS®... (truncated) amortization of $7.8 million, the portion of stock-based compensation expense recorded as cost of sales of $0.7 million and inventory step-up provision of $0.2 million.⁶

YTD 2026 REPORTABLE SEGMENT RESULTS

Cost of Commercial Product sales increased $2.2 million, or 4%, to $63.1 million for the six months ended June 30, 2026. The increase was primarily due higher KLOXXADO® sales and Canadian sales of branded NARCAN®, largely offset by lower sales volumes of OTC NARCAN® in the U.S.

Commercial Products gross margin decreased $19.7 million, or 60%, to $13.3 million for the six months ended June 30, 2026. Commercial Products gross margin percentage decreased 15 percentage points to 14% for the six months ended June 30, 2026. The decrease was largely due to an unfavorable price and volume mix of OTC NARCAN® across all U.S. sales channels and product mix due to the introduction of KLOXXADO®, partially offset by lower product costs related to the Canadian sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $18.9 million and the portion of stock-based compensation expense recorded as cost of sales of $0.1 million.⁷

Cost of MCM product sales increased $13.6 million, or 18%, to $89.6 million for the six months ended June 30, 2026. The increase was primarily due to higher cost of sales of BAT®,

CNJ-016®

(VIGIV) and BioThrax®, reflecting increased sales volumes as well as increased non-recurring manufacturing costs related to production of CYFENDUS®. These increases were partially offset by lower cost of sales for ANTHRASIL® and TEMBEXA® due to lower unit sales volume.

MCM Product gross margin increased $40.0 million, or 32%, to $165.4 million for the six months ended June 30, 2026. MCM Product gross margin percentage increased 3 percentage points to 61% for the six months ended June 30, 2026. The increase in gross margin percentage was primarily due to a favorable sales volume and product mix which was weighted more heavily towards higher margin products, the margin improvements were partially offset by non-recurring manufacturing costs mentioned above. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $14.8 million, the portion of stock-based compensation expense recorded as cost of sales of $1.2 million and inventory step-up provision of $0.3 million.⁸

2026 FINANCIAL FORECAST

The Company provides the following updated financial forecast for full year 2026, reflecting management's expectations based on the most current information available.

Q2 2026

FOOTNOTES

(1)

All financial information included in this release is unaudited.

(2)

See

“

Non-GAAP Financial Measures” and the “Reconciliation of Non-GAAP Financial Measures” tables for the definitions and reconciliations of Company-wide non-GAAP financial measures to the most closely related GAAP financial measures. Reconciliations of segment non-GAAP financial measures are included within the reportable segment tables. In the first quarter of 2026 we revised our calculations of these measures to exclude the impact of stock-based compensation expense, as this is a non-cash expense that is not related to our operating performance. The updated ranges for our 2026 forecast reflect this adjustment.

(3)

Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with GAAP.⁹

CONFERENCE CALL, PRESENTATION SUPPLEMENT AND WEBCAST INFORMATION

Company management will host a conference call at 5:00 pm eastern time today, August 5, 2026, to discuss these financial results. The conference call and presentation supplement can be accessed from the Company's website or through the following:

By phone

Advanced registration is required.

Visit https://register-conf.media-server.com/register/BI77a0454e68eb4a728e6c2ddddee54766 to register and receive an email with the dial-in number, passcode and registrant ID.

By webcast

Visit https://edge.media-server.com/mmc/p/fjwb9v5g/

A replay of the call can be accessed from the Emergent website.

ABOUT EMERGENT BIOSOLUTIONS INC.

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

NON-GAAP FINANCIAL MEASURES

In the accompanying analysis of financial information, we sometimes use information derived from consolidated and segment financial information that may not be presented in our financial statements or prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Certain of these financial measures are considered not in conformity with GAAP (“non-GAAP financial measures”) under the United States Securities and Exchange Commission (“SEC”) rules. Specifically, we have referred to the following non-GAAP financial measures:

• Adjusted Net Income

• Adjusted Net Income per Diluted Share

• Adjusted EBITDA

• Adjusted EBITDA Margin

• Adjusted Gross Margin

• Adjusted Gross Margin %

• Segment Adjusted Gross Margin

• Segment Adjusted Gross Margin %... (truncated)nges in fair value of financial instruments, stock-based compensation expense, loss on debt extinguishment, other, net, and tax effects. In the first quarter of 2026 we revised our calculation of these measures to exclude the impact of stock-based compensation expense, as this is a non-cash expense that is not related to our operating performance. We use Adjusted Net Income for the purpose of calculating Adjusted Net Income per Diluted Share. Management uses Adjusted Net Income per Diluted Share to assess total Company operating performance on a consistent basis. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with an additional understanding of our business operating results, including underlying trends.¹⁰

We define Adjusted EBITDA, which is a non-GAAP financial measure, as net income (loss) before depreciation and amortization, income taxes, total interest expense, net, impairments, inventory step-up provision, changes in fair value of financial instruments, severance and restructuring costs (benefits), acquisition and divestiture costs, loss on assets held for sale, contingent consideration milestones, stock-based compensation expense, loss on debt extinguishment, and other, net. We define Adjusted EBITDA Margin, which is a non-GAAP financial measure, as Adjusted EBITDA divided by Total Revenues. In the first quarter of 2026 we revised our calculation of these measures to exclude the impact of stock-based compensation expense, as this is a non-cash expense that is not related to our operating performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with a more complete understanding of our operating results, including underlying trends. In addition, EBITDA is a common alternative measure of operating performance used by many of our competitors. It is used by investors, financial analysts, rating agencies and others to value and compare the financial performance of companies in our industry, although it may be defined differently by different companies. Therefore, we also believe that this non-GAAP financial measure, considered along with corresponding GAAP financial measures, provides management and investors with additional information for comparison of our operating results with the operating results of other companies.

We define Adjusted Gross Margin, which is a non-GAAP financial measure, as Gross Margin, excluding the impact of intangible asset amortization, stock-based compensation expense, severance and restructuring costs (benefits) and inventory step-up provision. We define Adjusted Gross Margin %, which is a non-GAAP financial measure, as Adjusted Gross Margin as a percentage of Products and services sales, net. In the first quarter of 2026 we revised our calculation of these measures to exclude the impact of stock-based compensation expense, as this is a non-cash expense that is not related to our operating performance.

We define Segment Adjusted Gross Margin, which is a non-GAAP financial measure, as a segment's Gross Margin excluding the respective impact of intangible asset amortization, severance and restructuring costs (benefits), stock-based compensation expense and inventory step-up provision. We define Segment Adjusted Gross Margin %, which is a non-GAAP financial measure, as Segment Adjusted Gross Margin as a percentage of a segment's revenues. In the first quarter of 2026 we revised our calculation of these measures to exclude the impact of stock-based compensation expense, as this is a non-cash expense that is not related to segment operating performance.

Non-GAAP financial measures are not defined in the same manner by all companies and may not be comparable with other similarly titled measures of other companies. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Non-GAAP financial measures should be considered in addition to, but not as a substitute for or superior to, the information contained in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this press release.

SAFE HARBOR STATEMENT

Financial statements

Income Statement

Q2 2026 vs. Q2 2025 ($ in millions, except per share amounts)

Q2 2026Q2 2025% Change
Total Revenues234.3140.966.0%
Net Loss-180.2-12-1402.0%
Net Loss per Diluted Share-3.49-0.22-1486.0%
Adjusted Net Income (2)30.913.2134.0%
Adjusted Net Income per Diluted Share (2)0.60.24150.0%
Adjusted EBITDA (2)96.533.1192.0%
Net Loss Margin-77.0%-9.0%
Adjusted EBITDA Margin (2)41.0%23.0%
Gross Margin %50.0%36.0%
Adjusted Gross Margin % (2)58.0%49.0%

Income Statement

Year to Date ("YTD") 2026 vs YTD 2025 ($ in millions, except per share amounts)

YTD 2026YTD 2025% Change
Total Revenues390.4363.18.0%
Net Income (Loss)-173.456-410.0%
Net Income (Loss) per Diluted Share-3.350.99-438.0%
Adjusted Net Income (2)42.855.4-23.0%
Adjusted Net Income per Diluted Share (2)0.830.98-15.0%
Adjusted EBITDA (2)132112.218.0%
Net Income (Loss) Margin-44.0%15.0%
Adjusted EBITDA Margin (2)34.0%31.0%
Gross Margin %46.0%45.0%
Adjusted Gross Margin % (2)56.0%55.0%

Income Statement

— comprises revenues from the Services operating segment and contracts and grants revenues (in millions)

Q2 2026Q2 2025$ Change% Change
Naloxone52.467.5-15.1-22.0%
Anthrax MCM12.311.60.76.0%
Smallpox MCM101.640.661150.0%
Other Products54.16.247.9NM
Total Product sales, net220.4125.994.575.0%
All other revenues13.915-1.1-7.0%
Total revenues234.3140.993.466.0%

Income Statement

Operating Expenses (in millions)

Q2 2026Q2 2025$ Change% Change
Cost of product and services sales, net97.166.930.245.0%
Research and development (“R&D”)9.212.5-3.3-26.0%
Selling, general and administrative (“SG&A”)44.643.70.92.0%
Amortization of intangible assets17.216.216.0%
Impairment of long-lived assets191.3191.3NM
Total operating expenses359.4139.3220.1158.0%

Income Statement

Capital Expenditures (in millions)

Q2 2026Q2 2025% Change
Capital expenditures2.12.9-28.0%
Capital expenditures as a % of total revenues12

Income Statement

QUARTER 2026 REPORTABLE SEGMENT RESULTS (in millions)

Commercial Products – Quarter Ended June 30, – 2026Commercial Products – Quarter Ended June 30, – 2025Commercial Products – Quarter Ended June 30, – $ ChangeCommercial Products – Quarter Ended June 30, – % Change
Revenues52.467.5-15.1-22.0%
Cost of sales36.336.4-0.1
Intangible asset amortization9.49.4
Gross margin*6.721.7-15-69.0%
Gross margin %*1332
Add back:Intangible asset amortization9.49.4
Add back:Severance and restructuring costs0.2
Add back:Stock-based compensation expense0.1
Add back:Segment adjusted gross margin **16.231.3-15.1-48.0%
Add back:Segment adjusted gross margin % **3146

Income Statement (in millions)

MCM Products – Quarter Ended June 30, – 2026MCM Products – Quarter Ended June 30, – 2025MCM Products – Quarter Ended June 30, – $ ChangeMCM Products – Quarter Ended June 30, – % Change
Revenues16858.4109.6188.0%
Cost of sales52.825.827105.0%
Intangible asset amortization7.86.8115.0%
Gross margin*107.425.881.6NM
Gross margin %*6444
Add back:Intangible asset amortization7.86.8
Add back:Inventory step-up provision0.2
Add back:Severance and restructuring benefit-0.4
Add back:Stock-based compensation expense0.70.3
Add back:Segment adjusted gross margin**116.132.583.6NM
Add back:Segment adjusted gross margin %**6956

Income Statement

YTD 2026 REPORTABLE SEGMENT RESULTS (in millions)

Commercial Products – Six Months Ended June 30, – 2026Commercial Products – Six Months Ended June 30, – 2025Commercial Products – Six Months Ended June 30, – $ ChangeCommercial Products – Six Months Ended June 30, – % Change
Revenues95.3112.8-17.5-16.0%
Cost of sales63.160.92.24.0%
Intangible asset amortization18.918.9
Gross margin*13.333-19.7-60.0%
Gross margin %*1429
Add back:Intangible asset amortization18.918.9
Add back:Severance and restructuring costs0.2
Add back:Stock-based compensation expense0.1
Add back:Segment adjusted gross margin**32.352.1-19.8-38.0%
Add back:Segment adjusted gross margin %**3446

Income Statement (in millions)

MCM Products – Six Months Ended June 30, – 2026MCM Products – Six Months Ended June 30, – 2025MCM Products – Six Months Ended June 30, – $ ChangeMCM Products – Six Months Ended June 30, – % Change
Revenues269.821554.825.0%
Cost of sales89.67613.618.0%
Intangible asset amortization14.813.61.29.0%
Gross margin*165.4125.44032.0%
Gross margin %*6158
Add back:Intangible asset amortization14.813.6
Add back:Severance and restructuring benefit-1.2
Add back:Inventory step-up provision0.31.8
Add back:Stock-based compensation expense1.20.6
Add back:Segment adjusted gross margin**181.7140.241.530.0%
Add back:Segment adjusted gross margin %**6765

Income Statement

Updated Range (as of 08/05/2026) (in millions)

Updated Range (as of 08/05/2026)Previous Range (as of 04/30/2026)
Total revenues$645 - $675$720 - $760
Net loss$(245) - $(225)$(30) - $(10)
Adjusted net income (2)$10 - $30$45 - $65
Adjusted EBITDA (2)$130 - $150$155 - $175

Income Statement (in millions)

Updated Range (as of 08/05/2026)
Interest expense~$40
R&D~6% of Revenues
SG&A~27% to 28% of Revenues
Weighted avg. fully diluted share count~52
Stock-based compensation expense~$19
Capex~$17
Depreciation & amortization~$82

Income Statement

Q3 2026 Forecast — Q2 2026 (in millions)

Q3 2026 Forecast
Total revenues$110 - $130

Income Statement

Three Months Ended June 30, — (unaudited, in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues:Product and services sales, net226.8130.3376.5339.4
Revenues:Contracts and grants7.510.613.923.7
Revenues:Total revenues234.3140.9390.4363.1
Operating expenses:Cost of product and services sales, net (1)97.166.9169.1155.4
Operating expenses:Research and development9.212.519.727.6
Operating expenses:Selling, general and administrative44.643.791.296.1
Operating expenses:Amortization of intangible assets17.216.233.732.5
Operating expenses:Impairment of long-lived assets191.3191.3
Operating expenses:Total operating expenses359.4139.3505311.6
Operating expenses:Income (loss) from operations-125.11.6-114.651.5
Other income (expense):Interest expense-10-14.7-21-29.4
Other income (expense):Loss on assets held-for-sale-10.7-10.7-12.2
Other income (expense):Loss on debt extinguishment-20.5-20.5
Other income (expense):Other, net-3.713.966
Other income (expense):Total other income (expense), net-41.2-18.4-38.324.4
Other income (expense):Income (loss) before income taxes-166.3-16.8-152.975.9
Other income (expense):Income tax provision (benefit)13.9-4.820.519.9
Other income (expense):Net income (loss)-180.2-12-173.456
Earnings (loss) per common shareBasic-3.49-0.22-3.351.03
Earnings (loss) per common shareDiluted-3.49-0.22-3.350.99
Weighted average shares outstandingBasic51.654.251.754.3
Weighted average shares outstandingDiluted51.654.251.756.7

Income Statement

Three Months Ended June 30, — (1) (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss)-180.2-12-173.456
Adjustments:Depreciation & amortization2423.547.548.9
Adjustments:Income taxes13.9-4.820.519.9
Adjustments:Total interest expense, net9.213.419.427.4
Adjustments:Inventory step-up provision0.20.31.8
Adjustments:Severance and restructuring costs (benefits)0.50.50.7-0.8
Adjustments:Stock-based compensation expense6.94.68.86.1
Adjustments:Acquisition and divestiture costs0.2
Adjustments:Impairments191.3191.3
Adjustments:Loss on assets held-for-sale10.710.712.2
Adjustments:Contingent consideration milestones-5-50
Adjustments:Changes in fair value of financial instruments-0.52.9-9-6.6
Adjustments:Loss on debt extinguishment20.520.5
Adjustments:Other, net5-0.3-2.9
Adjustments:Total adjustments276.745.1305.456.2
Adjustments:Adjusted EBITDA96.533.1132112.2
Adjustments:Total revenues234.3140.9390.4363.1
Adjustments:Net income (loss) margin-77-9-4415
Adjustments:Adjusted EBITDA margin41233431

Income Statement

Three Months Ended June 30, — (1) (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Total revenues234.3140.9390.4363.1
Contracts and grants7.510.613.923.7
Product and services sales, net226.8130.3376.5339.4
Cost of product and services sales, net97.166.9169.1155.4
Intangible asset amortization17.216.233.732.5
Gross margin112.547.2173.7151.5
Gross margin %50364645
Add back:Intangible asset amortization17.216.233.732.5
Add back:Stock-based compensation expense0.90.31.40.6
Add back:Severance and restructuring costs (benefits)0.1-0.10.1-1
Add back:Inventory step-up provision0.20.31.8
Add back:Adjusted gross margin130.963.6209.2185.4
Add back:Adjusted gross margin %58495655

Income Statement

2026 Full Year Forecast — Reconciliation of Net Loss Forecast to Adjusted Net Income Forecast (in millions)

2026 Full Year Forecast – $(245) - $(225)
Inventory step-up provision4
Severance and restructuring costs11
Stock-based compensation expense19
Non-cash amortization charges63
Impairments191
Loss on assets held-for-sale11
Contingent consideration milestones-10
Changes in fair value of financial instruments-9
Loss on debt extinguishment21
Tax effect-46
Total adjustments:255
Adjusted net income$10 - $30

Income Statement

Reconciliation of Net Loss Forecast to Adjusted EBITDA Forecast (in millions)

2026 Full Year Forecast – $(245) - $(225)
Adjustments:Depreciation & amortization82
Adjustments:Income taxes15
Adjustments:Total interest expense, net40
Adjustments:Inventory step-up provision4
Adjustments:Severance and restructuring costs11
Adjustments:Stock-based compensation expense19
Adjustments:Impairments191
Adjustments:Loss on assets held-for-sale11
Adjustments:Contingent consideration milestones-10

Income Statement (in millions)

2026 Full Year Forecast
Total revenues$645 - $675
Contracts & Grants$(25) - $(25)
Product and services sales, net$620 - $650
Cost of product and services sales, net$365 - $369
Intangible asset amortization55
Gross margin$200 - $226
Gross margin %32% - 35%
Add back:Intangible asset amortization55
Add back:Inventory step-up provision4
Add back:Severance and restructuring costs1
Add back:Stock-based compensation expense3
Add back:Adjusted gross margin$263 - $289
Add back:Adjusted gross margin %42% - 44%

Balance Sheet

June 30, 2026 — (in millions, except per share data)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents139.7205.4
Current assets:Restricted cash1.23.7
Current assets:Accounts receivable, net19084.2
Current assets:Inventories, net303.6343.4
Current assets:Prepaid expenses and other current assets25.425.8
Current assets:Assets held-for-sale6.1
Current assets:Total current assets666662.5
Current assets:Property, plant and equipment, net178205.4
Current assets:Intangible assets, net261.8436.5
Current assets:Other assets1114.2
Current assets:Total assets1,116.81,318.6
Current liabilities:Accounts payable50.255.6
Current liabilities:Accrued expenses17.112.2
Current liabilities:Accrued compensation26.241.8
Current liabilities:Deferred revenue155
Current liabilities:Current tax liability4.46.8
Current liabilities:Other current liabilities9.910.8
Current liabilities:Total current liabilities122.8132.2
Current liabilities:Debt581.8572.1
Current liabilities:Deferred tax liability35.437.8
Current liabilities:Other liabilities35.453.9
Current liabilities:Total liabilities775.4796
Stockholders’ equity:Common stock, $0.001 par value per share; 200.0 shares authorized, 61.9 and 60.9 shares issued; 51.3 and 52.1 shares outstanding, respectively.0.10.1
Stockholders’ equity:Treasury stock, at cost, 10.7 and 8.7 common shares, respectively-270.5-252.6
Stockholders’ equity:Additional paid-in capital951.8942.4
Stockholders’ equity:Accumulated other comprehensive loss, net-6.8-7.5
Stockholders’ equity:Accumulated deficit-333.2-159.8
Stockholders’ equity:Total stockholders’ equity341.4522.6
Stockholders’ equity:Total liabilities and stockholders’ equity1,116.81,318.6

Cash Flow

Six Months Ended June 30, — (unaudited, in millions)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating ActivitiesNet income (loss)-173.456
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense8.86.1
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization47.548.9
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of deferred financing costs3.44.7
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes-2.44.7
Adjustments to reconcile net income to net cash provided by operating activities:Noncash loss on assets held-for-sale10.712.2
Adjustments to reconcile net income to net cash provided by operating activities:Change in fair value of warrant liability-8.9-6.6
Adjustments to reconcile net income to net cash provided by operating activities:Impairment of long-lived assets191.3
Adjustments to reconcile net income to net cash provided by operating activities:Loss on disposal of assets21.3
Adjustments to reconcile net income to net cash provided by operating activities:Other19.8-9.1
Changes in operating assets and liabilities:Accounts receivable-107.745.2
Changes in operating assets and liabilities:Inventories39.8-26.9
Changes in operating assets and liabilities:Prepaid expenses and other assets-0.629.2
Changes in operating assets and liabilities:Accounts payable-4.4-15.8
Changes in operating assets and liabilities:Accrued expenses and other liabilities1.2-28.3
Changes in operating assets and liabilities:Long-term incentive plan accrual0.41.6
Changes in operating assets and liabilities:Accrued compensation-16-26.3
Changes in operating assets and liabilities:Income taxes receivable and payable, net4.3-1.6
Changes in operating assets and liabilities:Contract liabilities6.5-0.1
Changes in operating assets and liabilities:Net cash provided by operating activities22.395.2
Investing ActivitiesPurchases of property, plant and equipment-4.5-6.5
Investing ActivitiesProceeds from sale of property, plant and equipment0.238.2
Investing ActivitiesMilestone payment from prior asset acquisition-50.4
Investing ActivitiesMilestone proceeds from prior asset divestiture50
Investing ActivitiesPurchase of convertible note receivable-5
Investing ActivitiesNet cash provided by (used in) investing activities-54.776.7
Financing ActivitiesPurchases of treasury stock-18-6.9
Financing ActivitiesProceeds from stock-based compensation activity1.40.8
Financing ActivitiesTaxes paid for stock-based compensation activity-3.2-0.7
Financing ActivitiesRepayment of prior term loan facility-150
Financing ActivitiesProceeds from the issuance of debt, net of lender fees145.5
Financing ActivitiesDebt issuance and extinguishment costs-11.5
Full release

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, acquisitions and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “confident,” “commit,” “forecast,” “future,” “outlook,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.¹¹

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasures (“MCM”) products, including CYFENDUS®

(Anthrax Vaccine Adsorbed (AVA) Adjuvanted), previously known as AV7909, ACAM2000®

(Smallpox and Mpox (Vaccinia) Vaccine, Live), CNJ-016®

(Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), BAT®

(Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), BioThrax®

(Anthrax Vaccine Adsorbed) Ebanga®

(ansuvimab-zykl) and/or TEMBEXA®

(brincidofovir) among others, as well as contracts related to development of medical countermeasures; our ability to meet our commitments to quality and compliance in all of our manufacturing operations; our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring; the commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN®

(naloxone HCL) Nasal Spray, over-the-counter NARCAN®

Nasal Spray and KLOXXADO®

Nasal Spray; our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries; the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations; our ability to collect reimbursement for raw materials and payment of service fees from our Bioservices customers; the results of pending government investigations and their potential impact on our business; our ability to satisfy the conditions of our litigation settlement agreements, and the potential impact of such agreements, including the funds to resolve related litigation, on our business; our ability to comply with the operating and financial covenants required by (i) our term loan facility under the Credit Agreement, dated April 16, 2026, by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent, (ii) our revolving credit facility under a credit agreement, dated September 30, 2024, among the Company, certain subsidiary borrowers, the lenders from time to time party thereto and Wells Fargo, National Association, as Agent, and (iii) our 3.875% Senior Unsecured Notes due 2028; our ability to maintain adequate internal control over financial reporting and to prepare accurate financial statements in a timely manner; our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future; our ability to invest in our business operations as a result of our current indebtedness; the impact of our share and debt repurchase programs; the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to FDA marketing authorization, and corresponding procurement by government entities outside the United States; the success of our commercialization, marketing and manufacturing capabilities and strategy; our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria; our ability to attract and retain qualified personnel; our ability to adequately secure and protect our intellectual property rights; the impact of cybersecurity incidents, including the risks from the unauthorized access, interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties; and the accuracy of our estimates regarding future revenues, expenses, capital requirements and need for additional financing. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ materially from our expectations in any forward-looking statement. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

Trademarks

Emergent®, BioThrax®, BaciThrax®, BAT®, Trobigard®, ANTHRASIL®, CNJ-016®, ACAM2000®, NARCAN®, CYFENDUS®, TEMBEXA® and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners, including KLOXXADO®, which is a registered trademark of Hikma Pharmaceuticals USA Inc.¹²

Emergent BioSolutions Inc.

Consolidated Balance Sheets

(in millions, except per share data)¹³

Emergent BioSolutions Inc.

Consolidated Statements of Operations

(unaudited, in millions, except per share data)¹⁴

Emergent BioSolutions Inc.

Consolidated Statements of Cash Flows

(unaudited, in millions)¹⁵

Emergent BioSolutions Inc.

Consolidated Statements of Cash Flows (Continued)

(unaudited, in millions)¹⁶

Emergent BioSolutions Inc.

Reconciliation of Non-GAAP Financial Measures... (truncated)sted Net Income per Diluted Share

(1)¹⁷

Emergent BioSolutions Inc.

Reconciliation of Net Income (loss) and Net Income (loss) Margin to Adjusted EBITDA and Adjusted EBITDA Margin

(1)¹⁸

Emergent BioSolutions Inc.

Reconciliations of Total Revenues to Product and Services Sales, Net and of Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin %

(1)¹⁹

Emergent BioSolutions Inc.

Reconciliation of Net Loss Forecast to Adjusted Net Income Forecast

Reconciliation of Net Loss Forecast to Adjusted EBITDA Forecast²⁰

Emergent BioSolutions Inc.

Reconciliations of Forecasted Total Revenues to Forecasted Product and Services Sales, Net and of Forecasted Gross Margin and Gross Margin % to Forecasted Adjusted Gross Margin and Adjusted Gross Margin %²¹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Emergent BioSolutions earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.